Cardiology
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics/Aging
Hematology/Oncology
Immunology/Allergy
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Psychiatry
Public Health, Policy, and Training
Pulmonary
Rheumatology
Surgery

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties

 


The New England Journal of Medicine: Search Results in Hematology\Oncology
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology\Oncology. NEJM (http://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
01/01/70 - Urothelial cancer is highly lethal in the metastatic state. Platinum-based combination chemotherapy remains the standard first-line treatment for metastatic disease. Carboplatin-based combinations are associated with a median overall survival of 9 months, and cisplatin-based combinations with a…

PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
01/01/70 - For more than two decades, the only therapy that was proven to extend overall survival among patients with advanced urothelial carcinoma was cisplatin-based combination chemotherapy. First-line cisplatin-based chemotherapy yields a median overall survival of 14 to 15 months, coupled with 5-year…

Case 5-2017: A 19-Year-Old Man with Hematuria and a Retroperitoneal Mass
01/01/70 - Presentation of Case. Dr. Jed-Sian Cheng (Urology): A 19-year-old man was seen in the urology outpatient clinic of this hospital because of a retroperitoneal mass and a history of transient hematuria. The patient had been in excellent health until approximately 1 month before this evaluation, when,…

Osimertinib or Platinum?Pemetrexed in EGFR T790M?Positive Lung Cancer
01/01/70 - Among patients with advanced non?small-cell lung cancer with a mutant epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy. Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after…

Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting
01/01/70 - Patients who undergo arthroscopic knee surgery and patients who are treated with casting of the lower leg are at increased risk for venous thromboembolism (i.e. deep-vein thrombosis or pulmonary embolism). Venous thromboembolism is an important health problem that is associated with considerable…

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
01/01/70 - The myelodysplastic syndrome (MDS) is clinically and biologically heterogeneous. In children and young adults, MDS can arise in the context of congenital mutations that cause bone marrow failure syndromes or inherited predisposition to myeloid cancers. Therapy-related MDS develops as a late…

Thromboprophylaxis after Knee Arthroscopy
01/01/70 - Prophylaxis for postoperative venous thromboembolism (VTE) should be tailored to the individual patient. In addition to considering the procedural risk of thrombosis and bleeding, we must assess the patient?s individual risk and willingness to accept risk. In this case, Ms. Benson is a good…

After the Fall ? Prophylaxis for All?
01/01/70 - Nearly 1 million patients undergo knee arthroscopy in the United States every year. The incidence of symptomatic venous thromboembolism in this patient population is approximately 0.6%, or nearly 4000 patients per year. Published evidence for the benefit of prophylactic anticoagulation in patients…

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
01/01/70 - Patients with localized prostatic cancer are often treated with radical prostatectomy. More than 30% of such patients will subsequently have recurrence. This recurrence manifests first as a rising serum level of prostate-specific antigen (PSA), termed biochemical recurrence. Large, retrospective…

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
01/01/70 - Sickle cell disease is characterized by the presence of sickle hemoglobin (HbS), chronic hemolysis, recurrent pain episodes (called sickle cell?related pain crises or vaso-occlusive crises), multiorgan dysfunction, and early death. Sickle cell?related pain crises are the primary cause of health…

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins